103 related articles for article (PubMed ID: 21083249)
1. Opinion: Microdosing: safer clinical trials and fewer animal tests.
Langley G; Farnaud S
Bioanalysis; 2010 Mar; 2(3):393-5. PubMed ID: 21083249
[No Abstract] [Full Text] [Related]
2. Welcome to 'microdosing'.
Ings RM
Bioanalysis; 2010 Mar; 2(3):371-2. PubMed ID: 21083244
[No Abstract] [Full Text] [Related]
3. Microdosing in early lead discovery.
Jekunen AP; Pauwels EK; Kairemo KJ
Bioanalysis; 2010 Mar; 2(3):421-8. PubMed ID: 21083252
[TBL] [Abstract][Full Text] [Related]
4. Trends in microdosing and other exploratory human pharmacokinetic studies for early drug development.
Oosterhuis B
Bioanalysis; 2010 Mar; 2(3):377-9. PubMed ID: 21083246
[No Abstract] [Full Text] [Related]
5. TGN1412: the catalyst for change?
Altern Lab Anim; 2006 Aug; 34(4):369-71. PubMed ID: 16969950
[No Abstract] [Full Text] [Related]
6. Value of new biomarkers for safety testing in drug development.
Hewitt P; Herget T
Expert Rev Mol Diagn; 2009 Sep; 9(6):531-6. PubMed ID: 19731999
[No Abstract] [Full Text] [Related]
7. Microdosing: the new pharmacokinetic paradigm?
Zanni GR; Wick JY
Consult Pharm; 2006 Oct; 21(10):756-76. PubMed ID: 17243857
[TBL] [Abstract][Full Text] [Related]
8. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
Soares HD
Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
[TBL] [Abstract][Full Text] [Related]
9. Accelerator mass spectrometry offers new opportunities for microdosing of peptide and protein pharmaceuticals.
Salehpour M; Ekblom J; Sabetsky V; Håkansson K; Possnert G
Rapid Commun Mass Spectrom; 2010 May; 24(10):1481-9. PubMed ID: 20411588
[TBL] [Abstract][Full Text] [Related]
10. Human microdosing; a boon or a bane?
Seth SD; Kumar NK; Dua P
Indian J Med Res; 2009 Aug; 130(2):202-4. PubMed ID: 19797820
[No Abstract] [Full Text] [Related]
11. Human microdosing for the prediction of patient response.
Henderson PT; Pan CX
Bioanalysis; 2010 Mar; 2(3):373-6. PubMed ID: 21083245
[No Abstract] [Full Text] [Related]
12. Phase I clinical trials: overcoming barriers.
Bates SE
Clin Cancer Res; 2010 Mar; 16(6):1709. PubMed ID: 20215552
[No Abstract] [Full Text] [Related]
13. Microdosing: current and the future.
Lappin G
Bioanalysis; 2010 Mar; 2(3):509-17. PubMed ID: 21083258
[TBL] [Abstract][Full Text] [Related]
14. [Introduction of anticancer agents to phase I clinical trials].
Shimoyama M
Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
[TBL] [Abstract][Full Text] [Related]
15. [The strategy of combination phase I/II study].
Murakami H; Ohe Y; Saijo N
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 trial disaster: the implications for research.
Torjesen I
Circulation; 2006 Jul; 114(3):f110-2. PubMed ID: 16869051
[No Abstract] [Full Text] [Related]
17. Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.
Garner RC
Bioanalysis; 2010 Mar; 2(3):429-40. PubMed ID: 21083253
[TBL] [Abstract][Full Text] [Related]
18. Better protection for human subjects is outcome of very early clinical trials.
Maloney DM
Hum Res Rep; 2006 May; 21(5):1-2. PubMed ID: 16832915
[No Abstract] [Full Text] [Related]
19. The elephant in the room.
Nature; 2006 Dec; 444(7121):790. PubMed ID: 17167433
[No Abstract] [Full Text] [Related]
20. Impact of NEDO project on microdosing clinical studies: toward the eIND study in Japan.
Yamashita S
Drug Metab Pharmacokinet; 2011; 26(6):549-50. PubMed ID: 22214558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
